 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for ACSL6 |
 Gene summary |
| Basic gene information | Gene symbol | ACSL6 |
| Gene name | acyl-CoA synthetase long-chain family member 6 | |
| Synonyms | ACS2|FACL6|LACS 6|LACS2|LACS5 | |
| Cytomap | UCSC genome browser: 5q31.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001009185.2, NM_001205247.1,NM_001205248.1,NM_001205250.1,NM_001205251.1, NM_015256.3, | |
| Description | fatty-acid-Coenzyme A ligase, long-chain 6long fatty acyl-CoA synthetase 2long-chain-fatty-acid--CoA ligase 6 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 604443 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000164398 | ||
| HPRD : 09190 | ||
| Vega : OTTHUMG00000150692 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ACSL6 | |
| BioGPS: 23305 | ||
| Pathway | NCI Pathway Interaction Database: ACSL6 | |
| KEGG: ACSL6 | ||
| REACTOME: ACSL6 | ||
| Pathway Commons: ACSL6 | ||
| Context | iHOP: ACSL6 | |
| ligand binding site mutation search in PubMed: ACSL6 | ||
| UCL Cancer Institute: ACSL6 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of ACSL6 | ||
| Description by TissGene annotations | Cancer gene Have significant anti-correlated miRNA Fused withOncogene Fused withTSGene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0001676 | long-chain fatty acid metabolic process | 20429931 | GO:0001676 | long-chain fatty acid metabolic process | 20429931 |
| Top |
| TissGeneExp for ACSL6 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| KICH | -0.555136361 | 1.695391639 | -2.250528 | 2.59E-06 | 9.08E-06 |
| HNSC | -2.637411895 | -1.401123523 | -1.236288372 | 1.12E-05 | 6.35E-05 |
| THCA | -2.801038462 | -0.900462191 | -1.900576271 | 5.57E-14 | 5.90E-13 |
| KIRC | -1.414425138 | 1.877081806 | -3.291506944 | 2.49E-32 | 5.64E-31 |
| KIRP | -1.878187986 | 1.803371389 | -3.681559375 | 5.17E-14 | 1.09E-12 |
| COAD | 1.880004563 | -1.898430053 | 3.778434615 | 1.57E-07 | 1.06E-06 |
| PRAD | -1.72060313 | -0.339764668 | -1.380838462 | 0.0019 | 0.005595138 |
| STAD | -2.079700486 | -0.429022361 | -1.650678125 | 0.000163 | 0.001174958 |
| Top |
| TissGene-miRNA for ACSL6 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| LUAD | hsa-miR-125b-5p | MIMAT0000423 | 0.049 | -0.26 | 60 |
| LUAD | hsa-let-7d-5p | MIMAT0000065 | 0.036 | -0.27 | 60 |
| UCS | hsa-miR-196a-5p | MIMAT0000226 | 0.042 | -0.27 | 56 |
| UCS | hsa-miR-181b-5p | MIMAT0000257 | 0.043 | -0.27 | 56 |
| LUAD | hsa-miR-24-3p | MIMAT0000080 | 0.012 | -0.32 | 60 |
| UCS | hsa-miR-374b-5p | MIMAT0004955 | 0.012 | -0.34 | 56 |
| UCS | hsa-miR-374a-5p | MIMAT0000727 | 0.0082 | -0.35 | 56 |
| Top |
| TissGeneMut for ACSL6 |
| TissGeneSNV for ACSL6 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.Q31K | COAD | 1 |
| p.Q229L | LIHC | 1 |
| p.L295R | LGG | 1 |
| p.F107L | COAD | 1 |
| p.D499N | SKCM | 1 |
| p.F355L | SKCM | 1 |
| p.V457A | UCEC | 1 |
| p.D153N | PRAD | 1 |
| p.H684Y | SKCM | 1 |
| p.P462L | SKCM | 1 |
| p.Q29* | HNSC | 1 |
| p.W486X | SKCM | 1 |
| p.T696K | LUSC | 1 |
| p.P208L | STAD | 1 |
| p.R365C | STAD | 1 |
| p.G103D | UCEC | 1 |
| p.V223M | PRAD | 1 |
| p.I541N | LUAD | 1 |
| p.R472Q | SARC | 1 |
| p.D518G | LUAD | 1 |
| p.R187C | STAD | 1 |
| p.P462L | OV | 1 |
| p.E596D | UCEC | 1 |
| p.S635F | SKCM | 1 |
| p.R11* | STAD | 1 |
| p.E416Q | SKCM | 1 |
| p.P510L | SKCM | 1 |
| p.P510S | SKCM | 1 |
| p.T698S | UCEC | 1 |
| p.C488Y | STAD | 1 |
| p.R427W | SARC | 1 |
| p.F230L | PAAD | 1 |
| p.D438Y | THYM | 1 |
| p.P201L | LUAD | 1 |
| p.E30D | UCEC | 1 |
| p.P335L | TGCT | 1 |
| p.A680V | UCEC | 1 |
| p.F47S | THYM | 1 |
| p.A62S | LUAD | 1 |
| p.V225M | STAD | 1 |
| p.P183L | STAD | 1 |
| p.A382V | SKCM | 1 |
| p.N652K | KIRC | 1 |
| p.E591K | UCEC | 1 |
| p.D474N | PAAD | 1 |
| p.W500* | SKCM | 1 |
| p.R472Q | STAD | 1 |
| p.I406V | LUAD | 1 |
| p.P208S | LIHC | 1 |
| p.R412C | LUAD | 1 |
| p.Q105* | SKCM | 1 |
| p.V200M | STAD | 1 |
| p.N307D | UCEC | 1 |
| p.Q638* | GBM | 1 |
| p.R566W | SKCM | 1 |
| p.G245C | LUAD | 1 |
| p.S343F | SKCM | 1 |
| p.L706M | KIRC | 1 |
| p.R447Q | STAD | 1 |
| p.G220F | LUAD | 1 |
| p.G567E | SKCM | 1 |
| p.R36Q | SKCM | 1 |
| p.P448L | COAD | 1 |
| p.S318Y | BLCA | 1 |
| p.T304M | UCEC | 1 |
| p.R412H | BRCA | 1 |
| p.I214F | KIRP | 1 |
| p.T304M | ESCA | 1 |
| p.H614R | SARC | 1 |
| p.P244T | KIRC | 1 |
| p.S298* | LUAD | 1 |
| p.L65F | SKCM | 1 |
| p.R33M | LUAD | 1 |
| p.M12T | LGG | 1 |
| p.G459R | LUAD | 1 |
| p.M26T | LGG | 1 |
| p.G245V | LUAD | 1 |
| p.D464Y | READ | 1 |
| p.R421H | UCEC | 1 |
| p.G469E | SKCM | 1 |
| p.A435V | BLCA | 1 |
| p.V175A | LUAD | 1 |
| p.I625T | LIHC | 1 |
| p.D485N | SKCM | 1 |
| p.R122H | UCEC | 1 |
| p.C337S | LIHC | 1 |
| p.I431V | LUAD | 1 |
| p.A460V | BLCA | 1 |
| p.R387C | LUAD | 1 |
| p.S128P | COAD | 1 |
| p.Q105E | CESC | 1 |
| p.G667E | SKCM | 1 |
| p.G455E | SKCM | 1 |
| p.I566N | LUAD | 1 |
| p.D504H | SKCM | 1 |
| p.G553E | COAD | 1 |
| p.Q610H | UCEC | 1 |
| p.S323* | LUAD | 1 |
| p.W308* | LUAD | 1 |
| p.D518H | SKCM | 1 |
| p.G161R | BRCA | 1 |
| p.R580W | SKCM | 1 |
| p.H349D | LUAD | 1 |
| p.F369L | SKCM | 1 |
| p.G529R | SKCM | 1 |
| p.A368V | SKCM | 1 |
| p.C463Y | STAD | 1 |
| Top |
| TissGeneCNV for ACSL6 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for ACSL6 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | BE766684 | ACSL6-ACSL6 | chr5:131325201 | chr5:131323885 | |
| Chimerdb3.0 | ChiTaRs | acute myeloid leukemia;chronic myeloid leukemia | AF102845 | ETV6-ACSL6 | chr12:11803094 | chr5:131308480 | |
| TCGAfusionPortal | PRADA | BRCA | TCGA-E9-A1RC-01A | PLIN1-ACSL6 | In-frame | Chr15:90212731 | Chr5:131321151 |
| Top |
| TissGeneNet for ACSL6 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| ACSL6, PHYH (tumor) | ACSL6, PHYH (normal) |
 |  |
| Top |
| TissGeneProg for ACSL6 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for ACSL6 |
| TissGeneDrug for ACSL6 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for ACSL6 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0036341 | Schizophrenia | 5 | BeFree,GAD,LHGDN |
| umls:C0004936 | Mental disorders | 1 | BeFree |
| umls:C0011853 | Diabetes Mellitus, Experimental | 1 | RGD |
| umls:C0021368 | Inflammation | 1 | RGD |
| umls:C0025322 | Premature Menopause | 1 | BeFree |
| umls:C0032463 | Polycythemia Vera | 1 | LHGDN |
| umls:C0036337 | Schizoaffective Disorder | 1 | BeFree |
| umls:C0040336 | Tobacco Use Disorder | 1 | GAD |
| umls:C0085215 | Ovarian Failure, Premature | 1 | BeFree,GAD |
| umls:C0236733 | Amphetamine-Related Disorders | 1 | CTD_human |
| umls:C0376358 | Malignant neoplasm of prostate | 1 | GAD |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |